Navigation Links
Research advances quest for HIV-1 vaccine

Scientists have uncovered new information that may help guide design of vaccines for HIV-1, the virus that causes AIDS. A new detailed structural analysis of the complex formed by an anti-HIV antibody called 4E10 and its specific target provides insight into why this particular antibody is so broadly effective, a rare characteristic for HIV discovered thus far. The research is published in the February issue of Immunity.

Vaccination has been a successful strategy for protecting humans from many potentially harmful viruses. However, designing a suitable vaccine for HIV-1 has been a highly challenging and thus far unsuccessful endeavor. HIV-1 is enormously variable and it has been difficult to isolate antibodies that will recognize the many different strains of the virus. The antibody 4E10 was derived from HIV-1 infected patients by Dr. Hermann Katinger in Vienna and is the broadest acting neutralizing antibody against HIV-1 that is currently known. This antibody recognizes a protein called gp41 that is found on the surface of the virus. The gp41 protein is thought to play a key role in mediating entry of HIV-1 into human cells.

A research group led by Drs. Dennis R. Burton and Ian A. Wilson from The Scripps Research Institute in La Jolla, California performed a study examining the detailed molecular structure of the complex formed when 4E10 binds to gp41 and determining how interaction of 4E10 with gp41 influences the virus.

X-ray crystallography was used to determine the structure of the complex formed by association of 4E10 with a peptide fragment that is identical to the section of gp41 that the antibody recognizes. The researchers identified the specific amino acids on gp41 that 4E10 interacts with and the 3D structure adopted by these amino acids. These study results suggest that 4E10 interacts with gp41 at a conserved region very close to the surface of the virus and they reveal some special characteristics of 4E10 that make it unusually effective at targeting this region.

Drs. Burton and Wilson are members of a scientific consortium of laboratories, the International AIDS Vaccine Initiative's Neutralizing Antibody Consortium (IAVI), which is focused on understanding broadly neutralizing antibodies at the molecular level and transferring this knowledge into the design of vaccines capable of stimulating broadly neutralizing antibodies against globally diverse HIV. According to Dr. Wayne Koff, IAVI Sr. VP for Vaccine Research, "Elucidation of the critical features of 4E10 recognition of HIV-1 helps to define potential immunogens able to elicit 4E10-like antibodies. This is an excellent example of the tremendous potential for accelerating HIV vaccine design when scientists from multidisciplinary laboratories come together to tackle a major scientific challenge. "

###

Rosa M.F. Cardoso, Michael B. Zwick, Robyn L. Stanfield, Renate Kunert, James M. Binley, Hermann Katinger, Dennis R. Burton, and Ian A. Wilson: "Broadly Neutralizing Anti-HIV Antibody 4E10 Recognizes a Helical Conformation of a Highly Conserved Fusion-Associated Motif in gp41"

Publishing in Immunity, Volume 22, Number 2, February 2005, pages 163?73. http://www.immunity.com/


'"/>

Source:Cell Press


Related biology news :

1. Researchers discover way to make cells in the eye sensitive to light
2. Quantum Dots Research Leads to New Knowledge about Protein Binding in Plants
3. Researchers find how protein allows insects to detect and respond to pheromones
4. Researchers Uncover Key Step In Manufacture of Memory Protein
5. Research on Worms Yields Clues on Aging
6. Researchers reveal the infectious impact of salmon farms on wild salmon
7. Researchers identify target for cancer drugs
8. Weill Cornell Research Reveals Secrets Of Trafficking Within Cells
9. Researchers discover molecule that causes secondary stroke
10. Researchers find missing genes of ancient organism
11. Researchers trace evolution to relatively simple genetic changes
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/3/2016)... --> --> Fourth quarter 2015:   ... fourth quarter of 2014. Gross margin was 46% (32). ... Earnings per share increased to SEK 6.39 (loss: 0.49). Cash ... --> --> January to December ... 1,142% compared with 2014. Gross margin was 43% (31). ...
(Date:2/2/2016)... 2, 2016 This BCC Research report ... by reviewing the recent advances in high throughput ... the field forward. Includes forecast through 2019. ... challenges and opportunities that exist in the bioinformatic ... developers, as well as IT and bioinformatics service ...
(Date:2/1/2016)... , February 1, 2016 Rising ... to drive global touchfree intuitive gesture control market ... Rising sales of consumer electronics coupled with new ... market size through 2020   ... coupled with new technological advancements to drive global touchfree ...
Breaking Biology News(10 mins):
(Date:2/11/2016)... ATLANTA , Feb. 11, 2016  Spectra BioPharma ... Organization (CSO) that provides biopharma companies the experience, ... implement and deploy outsourced sales teams. Created in ... team addresses both the strategic and tactical needs ... innovative sales solutions through both personal and non-personal ...
(Date:2/11/2016)... , Feb. 11, 2016  Dovetail Genomics™ LLC today ... beta program for a planned metagenomic genome assembly service. ... company,s metagenomic genome assembly method in a talk on ... Biology & Technology conference in Orlando, Fla. ... highly complex datasets is difficult. Using its proprietary ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... for more than 150 years, continues today to pursue the highest level of ... of analytical instruments: the AR9 Refractometer and the AR5 Refractometer. Accurate, reliable ...
(Date:2/10/2016)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a ... Mitsui & Co. Ltd., its partner in the ... investing an additional CDN$25 million in the joint venture ... 30% to 40%.  Mitsui will also play a stronger ... Sarnia , providing dedicated resources alongside ...
Breaking Biology Technology: